News Tarsus places $800m wager on Alkeus' Stargardt therapy Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."
News Tarsus gets first FDA nod for mite blepharitis therapy A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US.<
News Flagship joins three biotechs together to form Etcelera Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.